Stickler syndrome (hereditary arthro-ophthalmopathy) is a dominantly inherited connective tissue disorder with ocular, oro-facial, auditory and skeletal manifestations. It is genetically and phenotypically heterogeneous with the majority of families having mutations in the gene encoding type II collagen (COL2A1) and exhibiting a characteristic 'membranous' or type 1 vitreous phenotype. More recently a novel mutation in the gene encoding the α1 chain of type XI collagen (COL11A1) was reported in a Stickler syndrome pedigree with a different 'beaded' or type 2 vitreous phenotype. In the present study five more families with the type 2 vitreous phenotype were examined for linkage to four candidate genes: COL2A1, COL5A2, COL11A1 and COL11A2. Two families were linked to COL11A1 and sequencing identified mutations resulting in shortened α1(XI) collagen chains, one via exon skipping and the other via a multiexon deletion. One of the families showed weak linkage to COL5A2 but sequencing the open reading frame failed to identify a mutation. In the remaining two families all four loci were excluded by linkage analysis. These data confirm that mutations in COL11A1 cause Stickler syndrome with the type 2 vitreous phenotype and also reveal further locus heterogeneity.
Introduction
Stickler syndrome (hereditary arthro-ophthalmopathy; MIM108300; 184840) is a dominantly inherited disorder of connective tissue with characteristic ophthalmic, orofacial, auditory and articular manifestations. 1, 2 It is the commonest cause of inherited retinal detachment which is frequently bilateral and if untreated, leads to blindness. Abnormalities of vitreous formation and gel architecture are pathognomonic of Stickler syndrome. 3 Other characteristic features include congenital myopia (short-sight), midline clefting, a flattened mid-facial appearance, sensorineural hearing loss and joint hypermobility and later in life a degenerative arthropathy.
There is a variation in expression both within and between families. Linkage of the disorder to the gene for type II collagen (COL2A1) a major component of both cartilage and vitreous, has been shown in some families but not others. [4] [5] [6] [7] The first causative mutations in Stickler patients were identified in the COL2A1 gene, 8, 9 which was also mutated in the original Stickler kindred. 10 Mutations of various types have been found including deletions, mis-splicing and single base mutations. 11 So far, all have resulted in premature termination codons, leading to haploinsufficiency. Dominant negative changes in COL2A1 usually result in more severe phenotypes such as Kniest dysplasia and hypochondrogenesis. 11 We have previously reported that in Stickler syndrome two distinct vitreoretinal phenotypes can be recognised. [12] [13] [14] In the majority of patients an apparently vestigial vitreous gel occupies the immediate retrolental space and is bordered by a distinct folded membrane. We have referred to this characteristic 'membranous' anomaly as the type 1 vitreous phenotype and have shown that it correlates with defects in COL2A1. 12 In the remaining pedigrees there is a different phenotype with sparse fibre bundles of variable diameter coursing throughout an apparently otherwise optically empty vitreous cavity. We have referred to this 'beaded' or 'string of pearls' appearance as the type 2 vitreous phenotype and in these pedigrees linkage to COL2A1 has been excluded. 12, 13 These different vitreous phenotypes are illustrated in a recent review. 15 In one family with the type 2 vitreous phenotype, we have demonstrated linkage to COL11A1 13 and shown the causative mutation to be substitution of a glycine residue in the collagen helix, likely to have a dominant negative effect. 16 It is now apparent that that the quantitatively minor type V and XI collagens form heterotypic fibrils with the more abundant type II fibrillar collagen and help to regulate fibril assembly and diameter. 17, 18 Type XI collagen is more abundant in tissues expressing type II collagen so it is to be expected that mutations in either COL2A1 or COL11A1 can cause Stickler syndrome. However, COL11A2 is not expressed in the vitreous which explains why mutations in this gene give rise to some manifestations of Stickler syndrome but without eye abnormalities. [19] [20] [21] [22] In bovine vitreous it has been shown that the α2 chain of type XI collagen is replaced by the α2 chain of type V collagen, 23 a product of the COL5A2 gene, which can therefore also be considered as a candidate gene for Stickler syndrome.
The combination of phenotypic and genetic heterogeneity complicates the classification of Stickler syndrome and related disorders. A locus-based classification has been suggested 22 differentiating the full Stickler syndrome from the non-ocular variants although this is different from that given by OMIM (online Mendelian inheritance in man). Our clinical sub-classification 12 based on vitreous phenotype is more in harmony with the former and should not be confused with the locus-based classification of Stickler syndrome used in OMIM in which the designations STL1, STL2 and STL3 are assigned to COL2A1, COL11A2 and COL11A1 respectively.
In this study we report analysis of further families with the type 2 vitreous phenotype, characterise further mutations in COL11A1 and provide evidence for another Stickler syndrome locus.
Materials and Methods
The study was granted ethical approval (LRC92/019) and pedigrees were identified from the vitreoretinal service database at Addenbrooke's Hospital and subclassified according to phenotype prior to molecular genetic analysis. Since there are no definitive published criteria for the diagnosis of Stickler syndrome, a suggested protocol for diagnosis which was used in this study is given below: 1) Congenital abnormality of vitreous development, 12, 14, 15 and in addition, any three of the following features:
2) Stable congenital myopia with onset prior to 6 years of age;
3) Rhegmatogenous retinal attachment or paravascular pigmented lattice degeneration; 
Linkage Analysis
Primer sequences for markers close to the four candidate genes were obtained from the Généthon map 26 and Genemap. 27 Primers for the COL2A1 3' VNTR were as described previously. 12 Other markers used for COL2A1 were D12S85 and D12S83. Flanking markers D1S223, D1S206, D1S495 and D1S248 were used for COL11A1 and D6S105, D6S276, D6S291 were used for COL11A2. A dinucleotide repeat in intron 25 of COL3A1 28 was used as a marker for COL5A2, as these two genes are very closely related. 29 Additional markers used for COL5A2 were D2S389 and D2S2261. All of these markers were used to amplify polymorphic DNA variants from the subjects under investigation. One primer in each pair was end labelled with 33 P and then used in conjunction with the unlabelled primer in amplification reactions containing 20mM Tris HCl pH8.4, 50mM KCl, 5mM MgCl 2 , 200 µM dNTPs, 12.5 pmol of each primer and 0.5 units of Taq DNA polymerase in a volume of 12.5 µl. Standard cycling parameters were 95°C 1 min, 55°C 1 min and 72°C 1 min for 30 cycles. Products were analysed by electrophoresis in denaturing polyacrylamide gels and autoradiography. Lod scores were calculated using LIPED. 30 
Analysis of COL11A1
Amplification of COL11A1 cDNA was achieved using RNA from cultured dermal fibroblasts as previously described. 16 The complete open reading frame was amplified as seven overlapping products of around 900 bp. Larger products of around 3 kb were also synthesised using a different combination of the primers. In both instances a primary amplification reaction was re-amplified using a nested antisense primer to obtain the final cDNA product. For the larger cDNAs Superscript™ (Life Sciences) was used in the reverse transcription reactions and TaqPlus™ (Stratagene) was used in the amplification reactions, as recommended by the manufacturers.
Amplification of various regions of COL11A1 from genomic DNA was undertaken using TaqPlus, primers derived from the COL11A1 cDNA sequence (Genbank accession number J04177; J05407, 22 ), and the gene structure of COL11A2 31 as a guide to the exon/intron organisation of COL11A1. All amplified genomic products were partially sequenced to confirm the location of introns, and detect mutations in affected individuals. Analysis of DNA from individuals from family MS42 was achieved by amplification using primers derived from intron sequences, one upstream from the skipped exon and the other downstream. These were 5' ggtgcaattggcaggataaaagtag 3' (sense) and 5' gatgcattctcgaaggaattatgc 3' (antisense). The product was incubated with the restriction enzyme Sfc I at 37°C and then analysed by agarose gel electrophoresis.
Analysis of COL5A2
The strategy for analysis of COL5A2 cDNA was the same as for COL11A1. Primers were derived from the published cDNA sequences (Genbank accession number Y14690) and used to amplify six products covering bases 100-1419; 886-2133; 1624-3330; 2812-4047; 3190-4434; and 3937-4626. In addition larger products covering bases 100-2280; 2002-4626; and 498-4434 were amplified. In each case the primers corresponded to the first 24 sense and last 24 antisense bases. The smaller products were directly sequenced as above.
Results

Linkage Analysis
Linkage analysis was performed on five families with the type 2 vitreous phenotype using markers close to the COL2A1, COL5A2, COL11A1 and COL11A2 genes and the results are given in Table 1 . Loci were excluded if: a) Affected individuals were recombinant for a markers very close to the candidate genes (3' VNTR for COL2A1, and COL3A1 for COL5A2); or b) Affected individuals had inherited different haplotypes for flanking markers.
For families MS40 and MS42, COL11A1 was the best candidate with linkage to the other candidate loci excluded according to the criteria defined above. Clinical data for affected individuals from these pedigrees are given in Tables 2 and 3 respectively. Analysis of family MS40 showed that D1S495 was linked to the disorder (Z max 3.3, θ = 0), implicating COL11A1 as the disease locus. In family MS42 the disorder was linked to D1S206 (Z max 1.8, θ = 0). The loci COL2A1, COL11A1 and COL11A2 were excluded as the disease locus in family MS44. The COL5A2 locus could not be excluded and there was weak linkage to the D2S2261 marker (Z max 0.9, θ = 0). All four loci were excluded for families MS9 and MS32.
Mutation Detection
COL11A1 Amplification of COL11A1 cDNA was achieved using RNA from cultured dermal fibroblasts. Agarose gel electrophoresis of these products indicated (Figure 1 ). In the case of MS40 a smaller than expected band was seen in an amplification reaction encompassing bases 536-3551. Sequencing showed an in-frame deletion of 774 bp removing 258 amino acids from the helical region of the molecule (Figure 2a) . Amplification of genomic DNA, using primers either side of the deleted region resulted in a 7.1 kb product for all of the affected members of the family, but no product from normal individuals (Figure 2b ). It was therefore assumed that the 7.1 kb product presented the region of the mutant COL11A1 gene which contained a deletion. The genomic structure of COL11A1 is not yet known; however this deleted region of COL11A1 corresponds to exons 31-42 of COL11A2 which is 4 kb in length. Amplification of the same region of COL11A1 as a number of fragments showed that the exon/intron structure appeared to be the same as for COL11A2, but generally the introns were much larger (data not shown). This resulted in this region of COL11A1 being over 47 kb in length, meaning that around 40 kb was deleted in the mutant allele of MS40. The end points of the deletion were determined to be within two introns which were between bases 2663/2664 and bases 3437/3438 of the cDNA sequence and were 3.8 kb and 6.2 kb, respectively. Each of these introns contained a region of around 450 bp sharing approximately 95% identity. These sequences were homologous to a region in the L1 LINE family of repeats which are present throughout the human genome. 32 Recombination between these two sequences appears to have been responsible for the mutation.
Analysis of cDNA between bases 930-1892 from MS42 detected a smaller deletion. Cloning and sequencing showed a loss of 54 bp from the smaller RT-PCR product (data not shown). Amplification and sequencing of this region of the gene showed that the 54 bp corresponded to a complete exon (Gly16-Gln33), which was present in both alleles of an affected Stickler syndrome t individual. The 5' donor splice sequence of the following intron was found to be normal in both alleles. However, one allele had a single base deletion which altered the 3' acceptor splice site of the preceding intron, from the consensus ag to tg (Figure 3a) . This lead to skipping of the 54 bp exon from the mRNA, as seen in the RT-PCR product. The base pair deletion removed a Sfc I restriction site. Analysis of DNA from family members (Figure 3b) showed that whereas normal individuals were homozygous for the Sfc I site, affected members were heterozygous and therefore all possessed the 1 bp deletion.
COL5A2 Using cultured dermal fibroblast RNA from an individual of MS44, the cDNA for α2(V) collagen was amplified as 900 bp and larger (2-4 kb) overlapping products. No abnormalities in size were observed. Direct sequencing of the complete open reading frame did not detect a change likely to be a causative mutation. Polymorphisms were seen, providing evidence that both alleles were expressed and amplified. These polymorphisms also confirmed the haplotype analysis obtained with flanking markers.
Discussion
To date defects in two genes, COL2A1 and COL11A1 have been shown to cause the full Stickler syndrome phenotype, including ocular changes. 8, 9, 16, [33] [34] [35] [36] In addition mutations in COL11A2 lead to a 'Stickler-like' phenotype, but without ocular abnormalities. 19, 20, 22, 37 In collagen, is replaced by α2(V) collagen, which co-assembles with the products of the COL2A1 and COL11A1 genes. 23 Thus COL5A2 could also be considered as a candidate for Stickler syndrome. Relatively few COL2A1 Stickler mutations have been characterised 8, 9, [33] [34] [35] [36] and only one COL11A1 mutation, 16 In addition a COL11A1 exon skipping mutation has been described in the closely related Marshall syndrome. 38 Heterogeneity within the Stickler syndromes therefore poses a diagnostic dilemma for molecular genetic analysis in sporadic cases, and any clinical differences which arise from defects in the alternative genes could provide a valuable indication of the gene involved. Although our proposed sub-classification may not be favoured by the non-ophthalmologist, it is potentially more useful in the clinical setting than a locus-based classification which requires a lengthy laboratory-based diagnosis. It also has the potential to optimise and reduce any subsequent laboratory confirmation by indicating the likely, and perhaps more importantly the unlikely, candidate genes for analysis. In our experience the vitreous phenotypes are characteristic and unlike the skeletal or auditory changes, the vitreous presents a unique opportunity for the direct biomicroscopic observation of the abnormalities of connective tissue architecture 'in vivo'.
Slit lamp examination can detect two different vitreous phenotypes in families with Stickler syndrome. Systemic manifestations are similar and do not reliably distinguish between these two sub-groups.
14, 15 We have previously shown that one group of families with the type 1 'membranous' congenital vitreous anomaly were consistent with linkage to COL2A1. 12 We have confirmed our previous observation, that dominant negative mutations of COL11A1 cause Stickler syndrome with the type 2 vitreous phenotype. Here a further two families were found to be linked to that gene and the causative mutations characterised. Both lead to in-frame deletions from the triple helical region of the molecule, leaving an intact C-propeptide capable of heterotrimer formation with normal collagen α-chains. One mutation causes exon skipping, the other is a multi-exon deletion from the central portion of the gene. All three pedigrees exhibit the type 2 or 'beaded' vitreous anomaly. The exon/intron structure of the COL11A1 gene has not yet been determined and so we are not able to assign exon numbers to these deleted regions. However the limited analysis we have performed here, and previously, 16 suggests that at least for those regions coding for the collagen helix, the COL11A1 gene is identical in organisation to COL11A2. The exon skipping mutation would correspond to exon 15 in COL11A2 and the multi-exon deletion to exons 31-42. A major difference between COL11A1 and COL11A2 appears to be size. Most of the COL11A1 introns that we have amplified are larger than those of COL11A2. Indeed the deleted region in MS40 alone, at 40 kb, is larger than the 28 kb COL11A2 gene. 31 Another 54 bp exon-skipping mutation in COL11A1 caused Marshall syndrome 38 and it was suggested that this was due to the more disruptive type of mutation compared with the previous glycine substitution seen in this molecule. 16 The skipping mutation and the multi exon deletion described here should be just as disruptive as the mutant described as causing Marshall syndrome. Previously it had been thought that Marshall and Stickler syndromes may be one and the same and should not be segregated. 39, 40 Analysis of family MS44 with the type 2 vitreous abnormality, was consistent with COL5A2 as the disease locus. However, amplification of small and large cDNA products detected no deletions or insertions and sequencing of the complete open reading frame also revealed no significant changes. Polymorphisms were seen, indicating that both alleles were expressed, excluding a null allele. This in itself does not exclude COL5A2, but along with the observation that some patients with Ehlers-Danlos syndrome and COL5A2 mutations do not have vitreous changes, 41 it suggests that COL5A2 is not the disease locus in this family. This hypothesis is substantiated by the data excluding the four loci tested for both families MS9 and MS32 indicating that further heterogeneity within Stickler syndrome remains to be resolved.
In summary, our genetic analysis of families with Stickler syndrome has provided evidence for another Stickler syndrome locus associated with the type 2 vitreous phenotype. Dominant negative mutations of COL11A1 are associated with the type 2 vitreous phenotype in Stickler syndrome and this substantiates the clinical subclassification proposed previously. 12 
